PBM
FDMT icon

Propel Bio Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Propel Bio Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.36M Sell
252,654
-127,766
-34% -$1.24M 1.76% 20
2026
Q1 		$3.58M Buy
+380,420
New +$3.31M 2.26% 16

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Propel Bio Management's FDMT Position: Q2 2026 in Review

Propel Bio Management reduced its 4D Molecular Therapeutics (FDMT) stake by 34% in Q2 2026, selling an estimated $1.24M and leaving 252,654 shares worth $3.36M. The position accounts for 1.76% of the portfolio, ranked #20.

Propel Bio Management first reported a position in FDMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.58M in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Propel Bio Management held 252,654 shares of 4D Molecular Therapeutics worth $3.36M as of Q2 2026.
  • Propel Bio Management sold 127,766 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.24M.
  • 4D Molecular Therapeutics made up 1.76% of Propel Bio Management's portfolio in Q2 2026, its #20 holding.
  • Propel Bio Management first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Propel Bio Management's 4D Molecular Therapeutics position peaked at $3.58M in Q1 2026.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.